Joint National Committee VII and European Society of Hypertension/European Society of Cardiology guidelines for evaluating and treating hypertension: A two-way road?

Journal of the American Society of Nephrology

Volumn 16, Issue 3 SUPPL. 1, 2005, Pages

  Mancia, Giuseppe ^a   Grassi, Guido ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

CARDIOLOGY; CARDIOVASCULAR RISK; CONFERENCE PAPER; EUROPE; HUMAN; HYPERTENSION; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HOSPITALIZATION; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20844452686     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110963     Document Type: Conference Paper

References (26)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560-2571, 2003
2. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
3. Zanchetti A: Costs of implementing recommendations on hypertension management given in recent guidelines. J Hypertens 21: 2207-2209, 2003
4. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D; European Society of Cardiology Committee for Practice Guidelines: European Guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10: S1-S10, 2003
5. Zanchetti A, Hansson L, Menard J, Leonetti G, Rahn KH, Warnold I, Wedel H: Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT). J Hypertens 19: 819-825, 2001
6. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators: The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 361: 1149-1158, 2003
7. Moser M: The JNC VII: Stepped care is alive and well. Clin Hypertens 5: 187-190, 2003
8. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Oizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview or randomized drug trials in their epidemiological context. Lancet 335: 827-838, 1990
9. Blood Pressure Lowering Treatment Trialists' Collaboration: ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: Results of prospectively de-signed overviews of randomized trials. Lancet 356: 1955-1964, 2000
10. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretic for hypertension in the elderly. N Engl J Med 348: 583-592, 2003
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
12. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35: 1025-1030, 2000
13. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330: 1852-1857, 1994
14. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U: Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 34: 1129-1133, 1999
15. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-372, 2000
16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators: A calcium antagonist vs non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 290: 2805-2816, 2003
17. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MicroHOPE Substudy. Lancet 355: 253-259, 2000
18. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002
19. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 21: 875-886, 2003
20. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362: 777-781, 2003
21. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effects of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611-616, 1999
22. Alderman MH, Cohen H, Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension 33: 1130-1134, 1999
23. Skafors ET, Lithell HO, Selinus I, Aberg H: Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 298: 1147-1152, 1989
24. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O: Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study). J Hypertens 21: 1563-1574, 2003
25. Devereux RB, Watchtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou B, Rokkedal J, Dahlof B: Regression of left ventricular hypertrophy: Treatment effects and prognostic implications in the LIFE trial. J Hypertens 20: S4, 2002
26. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97: 48-54, 1998